$31.29
Price
$3.8B
Market Cap
18.1
P/E Ratio
10.0
Forward P/E
$1.73
EPS (TTM)
—
Dividend Yield
$756M
Cash
$3M
Total Debt
122M
Shares Out
$19.05
$32.56
52-Week Range
Institutional Ownership of CATALYST PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Fundsmith|Terry Smith
|
844.9K | $21M | $22.33 | +2.81% | |
|
Third Avenue Management|Matthew Fine
|
210.2K | $5M | $23.93 | +30.24% |
Trading Activity for CATALYST PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2026-Q1 | |||||
| SELL | -74.9% | 844.9K | $21M | $23.93 | |
| BUY | NEW | 210.2K | $5M | $23.93 | |
| 2025-Q3 | |||||
| BUY | +24.2% | 3.4M | $66M | $20.40 | |
| 2025-Q2 | |||||
| BUY | +25.9% | 2.7M | $59M | $23.65 | |
| 2025-Q1 | |||||
| BUY | NEW | 2.2M | $52M | $22.58 | |
Insider Trading for CATALYST PHARMACEUTICALS INC
6 Months Insider Sentiment
Buy $0
Sell $622K
0
Buys
3
Sells
-622K
Net
1
Grants
Largest
$360K
Harper
$156K
Harper
$116K
Harper
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 05, 2026 | Michael Wayne Kalb | Executive Vice President & CFO | EXERCISE | 7.1K | — | — |
| Jan 05, 2026 | Richard J Daly | President and CEO | EXERCISE | 42.1K | — | — |
| Dec 29, 2025 | Patrick J Mcenany | Director | EXERCISE | 26.3K | — | — |
| Dec 29, 2025 | Carmen Jeffrey Del | Chief Commercial Officer | EXERCISE | 8.7K | — | — |
| Dec 29, 2025 | Preethi Sundaram | Chief Strategy Officer | EXERCISE | 6.7K | — | — |
| Dec 29, 2025 | Richard J Daly | President and CEO | EXERCISE | 1.3K | — | — |
| Dec 29, 2025 | Donald A Denkhaus | Director | EXERCISE | 1.3K | — | — |
| Dec 29, 2025 | Brian Elsbernd | Chief Compliance/Legal Officer | EXERCISE | 6.7K | — | — |
| Dec 29, 2025 | Molly Harper | Director | EXERCISE | 1.3K | — | — |
| Dec 29, 2025 | David S Tierney | Director | EXERCISE | 1.3K | — | — |
| Dec 29, 2025 | Steve Miller | Chief Op. & Scientific Officer | EXERCISE | 14.0K | — | — |
| Dec 12, 2025 | Molly Harper | Director | SELL | 4.5K | $23.73 | $106K |
| Dec 12, 2025 | Molly Harper | Director | SELL | 6.7K | $23.06 | $156K |
| Dec 12, 2025 | Molly Harper | Director | SELL | 15.5K | $23.20 | $360K |
| Dec 12, 2025 | Molly Harper | Director | EXERCISE | 20.0K | $5.78 | $116K |
| Dec 08, 2025 | Tamar Thompson | Director | EXERCISE | 1.4K | — | — |
| Dec 08, 2025 | Carmen Jeffrey Del | Chief Commercial Officer | EXERCISE | 8.0K | — | — |
| Dec 08, 2025 | David S Tierney | Director | EXERCISE | 1.4K | — | — |
| Dec 08, 2025 | Donald A Denkhaus | Director | EXERCISE | 1.4K | — | — |
| Dec 08, 2025 | Molly Harper | Director | EXERCISE | 1.4K | — | — |
| Dec 08, 2025 | Patrick J Mcenany | Director | EXERCISE | 3.5K | — | — |
| Dec 08, 2025 | Preethi Sundaram | Chief Strategy Officer | EXERCISE | 6.9K | — | — |
| Dec 08, 2025 | Steve Miller | Chief Op. & Scientific Officer | EXERCISE | 11.9K | — | — |
| Dec 08, 2025 | Brian Elsbernd | Chief Compliance/Legal Officer | EXERCISE | 7.1K | — | — |
| Dec 01, 2025 | Patrick J Mcenany | Director | GRANT | 45.0K | — | — |